{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:41:12Z","timestamp":1788892872538,"version":"build-2803163510"},"reference-count":52,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Increased resistance to \u03b2-lactams\/\u03b2-lactamase inhibitors by mutations in \u03b2-lactamase genes, porins, and efflux pumps complicates the management of carbapenem-resistant\n                      <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                      (CRKP). Polymyxin B (PMB)-based combination therapy is the best alternative treatment for middle and low-income countries that cannot access the latest medicines. It is crucial to know both phenotypic and genotypic characteristics of a pathogen to understand the killing effect of each drug and its combinations. Hence, our objective was to incorporate mechanistic insights gained from resistance mechanisms of each isolate to develop a mechanism-based pharmacokinetic\/pharmacodynamic model. Six clinical CRKP isolates with diverse genotypic resistance expressing\n                      <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                      <jats:sub>KPC<\/jats:sub>\n                      ,\n                      <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                      <jats:sub>NDM<\/jats:sub>\n                      , porin, and mgrB mutations were used for static concentration time kill (SCTK) assays to evaluate the rate and extent of killing by monotherapy, double and triple combinations using PMB (0.5\u201364 mg\/L), meropenem (10\u2013120 mg\/L), and fosfomycin (75\u2013500 mg\/L). Isolate BRKP28 expressed non-functional MgrB (a regulatory protein) and high-level phenotypic resistance (PMB MIC: &gt;128 mg\/L). In line with the observed resistance, the model estimated that BRKP28 had a reduced maximum killing rate constant for PMB (3.61 h\u207b\u00b9) relative to other isolates. The mechanistic synergy of PMB, due to outer membrane disruption, was incorporated into three isolates with porin mutations. PMB demonstrated 83%\u201388% mechanistic synergy with meropenem and 81%\u201398% with fosfomycin. The model further estimated that a very low concentration of PMB (0.49\u20130.64 mg\/L) was sufficient to achieve 50% of the maximum synergy. Simulations using population pharmacokinetic models showed that combination therapy of PMB (1 mg\/kg q12h) and fosfomycin (8 g q8h) achieved &gt;73% reduction in area under the bacterial load-versus-time curve across four isolates. The triple combination therapy achieved a 67.7% reduction in non-carbapenamase producing isolate. These findings demonstrates that a low PMB dosing regimen (1 mg\/kg q12h) can produce synergistic effects in combination therapy and may be effective in managing infections caused by CRKP, including PMB resistant isolates.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.00782-25","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T14:00:15Z","timestamp":1766152815000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":4,"title":["A mechanism-based pharmacokinetic\/pharmacodynamic analysis of polymyxin B-based combination therapy against carbapenem-resistant\n                    <i>Klebsiella pneumoniae<\/i>\n                    isolates with diverse phenotypic and genotypic resistance mechanisms"],"prefix":"10.1128","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3951-1146","authenticated-orcid":true,"given":"Ramya","family":"Mahadevan","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"Titus Family Department of Clinical Practice, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California","place":["Los Angeles, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefany","family":"Garcia","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0130frc33","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Pharmaceutics and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill","place":["Chapel Hill, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajnikant","family":"Sharma","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"Titus Family Department of Clinical Practice, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California","place":["Los Angeles, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3285-8768","authenticated-orcid":true,"given":"Hongqiang","family":"Qiu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0130frc33","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Pharmaceutics and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill","place":["Chapel Hill, USA"]},{"id":[{"id":"https:\/\/ror.org\/055gkcy74","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy, Fujian Medical University Union Hospital","place":["Fuzhou, People\u2019s Republic of China"]},{"id":[{"id":"https:\/\/ror.org\/050s6ns64","id-type":"ROR","asserted-by":"publisher"}],"name":"College of Pharmacy, Fujian Medical University","place":["Fuzhou, People's Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elsheikh","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0130frc33","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Pharmaceutics and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill","place":["Chapel Hill, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Parambi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0130frc33","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Pharmaceutics and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill","place":["Chapel Hill, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cely Saad","family":"Abboud","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04spxqa35","id-type":"ROR","asserted-by":"publisher"}],"name":"Instituto Dante Pazzanese de Cardiologia","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Pasteran","sequence":"additional","affiliation":[{"name":"Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas, Antimicrobial Service of the National Institute of Infectious Diseases (ANLIS Dr. Carlos G. Malbr\u00e1n)","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9904-7890","authenticated-orcid":true,"given":"Maria Soledad","family":"Ramirez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/057bq1s94","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton","place":["Fullerton, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S.","family":"Kaye","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Infectious Diseases, Rutgers Robert Wood Johnson Medical School","place":["New Brunswick, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3299-894X","authenticated-orcid":true,"given":"Robert A.","family":"Bonomo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02x4b0932","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine","place":["Cleveland, USA"]},{"id":[{"id":"https:\/\/ror.org\/051fd9666","id-type":"ROR","asserted-by":"publisher"}],"name":"CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES)","place":["Cleveland, USA"]},{"id":[{"id":"https:\/\/ror.org\/01nh3sx96","id-type":"ROR","asserted-by":"publisher"}],"name":"Geriatric Research Education and Clinical Center, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Education and Clinical Center","place":["Cleveland, USA"]},{"id":[{"id":"https:\/\/ror.org\/02x4b0932","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medicine, Case Western Reserve University School of Medicine","place":["Cleveland, USA"]},{"id":[{"id":"https:\/\/ror.org\/02x4b0932","id-type":"ROR","asserted-by":"publisher"}],"name":"Departments of Pharmacology, Biochemistry, Proteomics and Bioinformatics, Case Western Reserve University School of Medicine","place":["Cleveland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8704-7770","authenticated-orcid":true,"given":"Gauri G.","family":"Rao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"Titus Family Department of Clinical Practice, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California","place":["Los Angeles, USA"]},{"id":[{"id":"https:\/\/ror.org\/0130frc33","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Pharmaceutics and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill","place":["Chapel Hill, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2024.03.020"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw649"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ837"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.09.031"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/17460913.2025.2468112"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2950"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae048"},{"key":"e_1_3_2_10_2","unstructured":"NIAID. 2019. NIAID\u2019s antibiotic resistance research framework: current status and future directions. Bethesda MD USA National Institute of Allergy and Infectious Diseases"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01222-13"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00080"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06268-11"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2209"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2200131"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30099-9"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12020237"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.05.018"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2024.06.007"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2020.05.001"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01694-17"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01165-15"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv135"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2197"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.03.007"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02166-13"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2009.02921.x"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.10.025"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpj.2018.12.002"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz181"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025288"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku323"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90709-2"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02875-z"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15061"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx209"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00074"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2019.00151"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx269"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13870"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/12.4.357"},{"key":"e_1_3_2_42_2","volume-title":"M100 Ed34Performance standards for antimicrobial susceptibility testing","author":"CLSI","year":"2024","unstructured":"CLSI. 2024. M100 Ed34. Performance standards for antimicrobial susceptibility testing. 34th ed. Clinical & Laboratory Standards Institute.","edition":"34"},{"key":"e_1_3_2_43_2","unstructured":"EUCAST. 2025. Clinical Breakpoint Tables v. 15.0 valid from 2025-01-01. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_15.0_Breakpoint_Tables.pdf. Retrieved 26 Sep 2025."},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr563"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00285-06"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02121-16"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.06.016"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae111"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00591-22"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00092-13"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00489-08"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1023\/a:1012299115260"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9257-x"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00782-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00782-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T14:02:14Z","timestamp":1770213734000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00782-25"}},"subtitle":[],"editor":[{"given":"James E.","family":"Leggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,4]]}},"alternative-id":["10.1128\/aac.00782-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.00782-25","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.05.06.652358","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"2025-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00782-25"}}